We're in.

Trilliome has been selected for the MassChallenge Switzerland 2026 cohort.

For those new here: we're a healthcare company built on the biology of the gut. We make precision bioactives — plant-derived actives that target thebiology of healthy aging at milligrams, not grams, and formulate into any format.Why this matters to us right now is simple. MassChallenge is equity-free. Mentors, corporate partners, and a serious peer cohort - without giving upa single share. For a company that puts its capital into science and evidence rather than marketing, that is exactly the kind of support that compounds.

And the timing is good: we're heading into our first regulatory clearances and first revenue, and the conversations this program opens (corporates,formulators, fellow founders) are exactly the ones we want to be having this year.